Patents by Inventor Mitchell J. Fruitstone

Mitchell J. Fruitstone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reduced IgG in low ionic strength medium for immunohematologic agglutination
    Patent number: 4540565
    Abstract: An antiserum for immunohematologic agglutination reactions involving IgG antibodies wherein reduced IgG antibodies are suspended in a low ionic strength medium.
    Type: Grant
    Filed: August 13, 1981
    Date of Patent: September 10, 1985
    Assignee: American Hospital Supply Corporation
    Inventors: Daniel P. Roman, Jr., Mitchell J. Fruitstone
  • Suspending medium for immunologic reactions
    Patent number: 4379847
    Abstract: A low ionic strength suspending medium for immunologic reactions which includes a salt solution, a buffer, gelatin, albumin, and an organic solute to control osmolality.
    Type: Grant
    Filed: January 14, 1981
    Date of Patent: April 12, 1983
    Assignee: American Hospital Supply Corporation
    Inventors: Mitchell J. Fruitstone, Michele M. Tilly, Betty G. Pixton
  • Suspending medium for immunologic reactions
    Patent number: 4259207
    Abstract: A low ionic strength suspending medium for immunologic reactions which includes a salt solution, a buffer, gelatin, albumin, and an organic solute to control osmolality.
    Type: Grant
    Filed: September 19, 1979
    Date of Patent: March 31, 1981
    Assignee: American Hospital Supply Corporation
    Inventors: Mitchell J. Fruitstone, Michele M. Tilly, Betty G. Pixton
  • Method of preparing C3-sensitized erythrocytes
    Patent number: 4247536
    Abstract: A set of four cell suspensions containing erythrocytes monospecifically sensitized with IgG, IgM, C3, and C4. The suspensions provide control cells to determine the purity and strength of the antibodies to these immunoglobins or complement components contained in antisera used for clinical testing. Strict control of the pH, temperature, and EDTA concentration of a solution to which blood is added allows for the elective production of C3- or C4-sensitized cells. Selecting a serum with IgG or IgM antibodies and inactivating undesired proteins permits the production IgG- or IgM-sensitized cells. The resultant cells have agglutination reaction strengths of about 2-4+. Erythrocytes from humans or other animals may undergo the monospecific sensitization. Other human proteins, such as IgA or C5, and plasma proteins from other animals may similarly be attached monospecifically to red blood cells.
    Type: Grant
    Filed: March 20, 1978
    Date of Patent: January 27, 1981
    Assignee: American Hospital Supply Corporation
    Inventors: Mitchell J. Fruitstone, Jose Carro, Betty G. Pixton